Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Apogee Therapeutics (Nasdaq: APGE) has scheduled a conference call and webcast for March 3, 2025, at 8:30 a.m. ET to present interim results from its Phase 1 healthy volunteer trial of APG990. The clinical-stage biotechnology company, which focuses on developing novel biologics for inflammatory and immunology (I&I) conditions, will also discuss combination strategy plans for APG777 + APG990.
The company's therapeutic pipeline targets major I&I markets, including:
- Atopic dermatitis (AD)
- Asthma
- Eosinophilic esophagitis (EoE)
- Chronic obstructive pulmonary disease (COPD)
The live webcast will be accessible through the company's investor relations website, with a replay available after the call.
Apogee Therapeutics (Nasdaq: APGE) ha programmato una conferenza telefonica e un webcast per il 3 marzo 2025, alle 8:30 ET, per presentare i risultati intermedi del suo studio di fase 1 su volontari sani relativo a APG990. L'azienda biotecnologica in fase clinica, focalizzata sullo sviluppo di nuovi biologici per condizioni infiammatorie e immunologiche (I&I), discuterà anche le strategie di combinazione per APG777 + APG990.
Il pipeline terapeutico dell'azienda mira a importanti mercati I&I, tra cui:
- Dermatite atopica (AD)
- Asma
- Esofagite eosinofila (EoE)
- Malattia polmonare ostruttiva cronica (COPD)
Il webcast in diretta sarà accessibile attraverso il sito web delle relazioni con gli investitori dell'azienda, con una registrazione disponibile dopo la chiamata.
Apogee Therapeutics (Nasdaq: APGE) ha programado una conferencia telefónica y un webcast para el 3 de marzo de 2025, a las 8:30 a.m. ET, para presentar los resultados intermedios de su ensayo de fase 1 en voluntarios sanos sobre APG990. La empresa biotecnológica en etapa clínica, que se centra en el desarrollo de nuevos biológicos para condiciones inflamatorias e inmunológicas (I&I), también discutirá las estrategias de combinación para APG777 + APG990.
El pipeline terapéutico de la empresa se dirige a importantes mercados de I&I, incluyendo:
- Dermatitis atópica (AD)
- Asma
- Esofagitis eosinofílica (EoE)
- Enfermedad pulmonar obstructiva crónica (EPOC)
El webcast en vivo será accesible a través del sitio web de relaciones con inversores de la empresa, con una repetición disponible después de la llamada.
Apogee Therapeutics (Nasdaq: APGE)는 2025년 3월 3일 오전 8시 30분 ET에 APG990에 대한 건강한 자원봉사자를 대상으로 한 1상 시험의 중간 결과를 발표하기 위한 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다. 염증 및 면역학(I&I) 질환을 위한 새로운 생물학적 제제 개발에 중점을 둔 임상 단계의 생명공학 회사는 APG777 + APG990에 대한 조합 전략 계획도 논의할 것입니다.
회사의 치료 파이프라인은 주요 I&I 시장을 목표로 하고 있으며, 포함되는 질환은 다음과 같습니다:
- 아토피 피부염 (AD)
- 천식
- 호산구 식도염 (EoE)
- 만성 폐쇄성 폐질환 (COPD)
실시간 웹캐스트는 회사의 투자자 관계 웹사이트를 통해 접근 가능하며, 통화 후 재생이 가능합니다.
Apogee Therapeutics (Nasdaq: APGE) a programmé une conférence téléphonique et un webinaire pour le 3 mars 2025 à 8h30 ET afin de présenter les résultats intermédiaires de son essai de phase 1 sur des volontaires sains concernant APG990. L'entreprise biopharmaceutique en phase clinique, qui se concentre sur le développement de nouveaux biologiques pour les conditions inflammatoires et immunologiques (I&I), discutera également des stratégies de combinaison pour APG777 + APG990.
Le pipeline thérapeutique de l'entreprise cible des marchés I&I majeurs, notamment :
- Dermatite atopique (AD)
- Asthme
- Œsophagite éosinophilique (EoE)
- Maladie pulmonaire obstructive chronique (MPOC)
Le webinaire en direct sera accessible via le site des relations investisseurs de l'entreprise, avec une rediffusion disponible après l'appel.
Apogee Therapeutics (Nasdaq: APGE) hat eine Telefonkonferenz und einen Webcast für den 3. März 2025 um 8:30 Uhr ET angesetzt, um die vorläufigen Ergebnisse seiner Phase-1-Studie mit gesunden Freiwilligen zu APG990 zu präsentieren. Das biopharmazeutische Unternehmen in klinischer Phase, das sich auf die Entwicklung neuartiger Biologika für entzündliche und immunologische (I&I) Erkrankungen konzentriert, wird auch die Kombinationsstrategie für APG777 + APG990 besprechen.
Die therapeutische Pipeline des Unternehmens zielt auf wichtige I&I-Märkte ab, darunter:
- Atopische Dermatitis (AD)
- Asthma
- Eosinophile Ösophagitis (EoE)
- Chronisch obstruktive Lungenerkrankung (COPD)
Der Live-Webcast wird über die Investor-Relations-Website des Unternehmens zugänglich sein, mit einer Wiederholung, die nach dem Anruf verfügbar ist.
- None.
- None.
Webcast to be held Monday, March 3rd at 8:30 a.m. ET
SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for its combination approach for APG777 + APG990.
Webcast Details
Apogee Therapeutics’ live webcast of the APG990 interim Phase 1 results will begin on Monday, March 3rd at 8:30 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, COPD and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com
FAQ
When will Apogee Therapeutics (APGE) report Phase 1 interim results for APG990?
What therapeutic areas does APGE's pipeline target?
What will be discussed in APGE's March 3rd conference call?
How can investors access APGE's March 3rd webcast?
